Saturday 17 October 2026
Export TRVN’s income statement to Excel — free account
Trevena, Inc.
TRVN Healthcare Biotechnology
Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.07
−100.00%
Follow TRVN
Trevena, Inc. (TRVN) P/E ratio
Trevena, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| 22 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NEXI NexImmune, Inc. compare | n/m |
| BRTX Biorestorative Therapies, Inc. compare | n/m |
| SILO Silo Pharma, Inc. compare | n/m |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| CLSDQ Clearside Biomedical, Inc. compare | n/m |
| TRVN Trevena, Inc. | n/m |
| ITRMF Iterum Therapeutics PLC compare | n/m |
| GNPX GENPREX compare | 0.0× |
| OGEN Oragenics, Inc. compare | 0.4× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)